Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Mesoblast Limited ( (AU:MSB) ).
Mesoblast Limited has announced a change in the interest of its director, Dr. Silviu Itescu, in the company’s securities. The change involves the acquisition of 3,108,000 options, bringing the total number of options held by Dr. Itescu to 16,449,558, following shareholder approval at the 2024 Annual General Meeting. This adjustment in director’s interest reflects the company’s ongoing governance and shareholder engagement practices, potentially impacting investor perceptions and the company’s market dynamics.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on the development and commercialization of innovative cellular medicines. The company’s primary products are based on its proprietary mesenchymal lineage adult stem cell technology, targeting conditions such as inflammatory diseases, cardiovascular diseases, and orthopedic disorders.
YTD Price Performance: -37.73%
Average Trading Volume: 365,896
Technical Sentiment Signal: Sell
Current Market Cap: $1.35B
See more insights into MSB stock on TipRanks’ Stock Analysis page.